Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Piyanling liniment is a topical pharmaceutical preparation developed by the 71st Group Army Hospital of the Chinese People's Liberation Army (CPLA), formerly known as the 97th Hospital. It is a hospital-made preparation (医院制剂) specifically formulated for the treatment of chronic inflammatory and pruritic skin conditions, including neurodermatitis and chronic eczema. The formulation typically functions as a combination therapy, utilizing a corticosteroid (such as dexamethasone) to provide potent anti-inflammatory and immunosuppressive effects, alongside antipruritic agents like camphor and menthol which offer cooling and soothing relief from itching. It may also contain salicylic acid for its keratolytic properties, which help to soften and remove thickened skin scales. As a liniment (spirit-based solution), it is designed for topical application to facilitate the penetration of active ingredients into the affected dermal layers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on piyanling liniment.